Compare · FRMM vs NVO
FRMM vs NVO
Side-by-side comparison of Forum Markets Incorporated (FRMM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRMM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 2814.4x FRMM ($76.7M).
- Over the past year, FRMM is down 81.4% and NVO is down 29.3% - NVO leads by 52.1 points.
- FRMM has been more active in the news (10 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for FRMM).
- Company
- Forum Markets Incorporated
- Novo Nordisk A/S
- Price
- $5.66-1.74%
- $48.78+1.22%
- Market cap
- $76.7M
- $215.95B
- 1M return
- +12.30%
- +2.89%
- 1Y return
- -81.44%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 10
- 4
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FRMM
- Large owner Lomashuk Konstantin sold $1,500,000 worth of shares (250,000 units at $6.00) (SEC Form 4)
- Forum Markets to Present Company Strategy and Business Model at Force Family Office Investor Webinar
- Large owner Lomashuk Konstantin sold $16,141 worth of shares (2,562 units at $6.30) (SEC Form 4)
- Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Forum Markets Acquires Aircraft Engine for Approximately $12 Million, Advances Plan to Expand Aviation Portfolio to Five Engines
- Large owner Lomashuk Konstantin sold $20,846 worth of shares (3,387 units at $6.15) (SEC Form 4)
- Large owner Lomashuk Konstantin sold $30,477 worth of shares (4,802 units at $6.35) (SEC Form 4)
- SEC Form DEFA14A filed by Forum Markets Incorporated
- SEC Form DEF 14A filed by Forum Markets Incorporated
- New insider Pemble Brian James claimed ownership of 1,451,714 shares (SEC Form 3)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S